# Cancer Associated Thrombosis and Isoquercetin (CATIQ)

> **NCT02195232** · PHASE2,PHASE3 · COMPLETED · sponsor: **Jeffrey Zwicker, MD** · enrollment: 64 (actual)

## Conditions studied

- Thromboembolism of Vein VTE in Colorectal Cancer
- Thromboembolism of Vein in Pancreatic Cancer
- Thromboembolism of Vein in Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Isoquercetin

## Key facts

- **NCT ID:** NCT02195232
- **Lead sponsor:** Jeffrey Zwicker, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2018-12
- **Final completion:** 2019-10-22
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2021-03-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02195232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02195232, "Cancer Associated Thrombosis and Isoquercetin (CATIQ)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02195232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*